You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: February 17, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MEDI4736

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug MEDI4736?

MEDI4736 is an investigational drug.

There have been 256 clinical trials for MEDI4736. The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2019.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).

There are twenty-three US patents protecting this investigational drug and seven hundred and seventy-eight international patents.

Recent Clinical Trials for MEDI4736
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyAstraZenecaPhase 2
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE StudyNational Cancer Institute (NCI)Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaAstraZenecaPhase 3

See all MEDI4736 clinical trials

Clinical Trial Summary for MEDI4736

Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736

See all MEDI4736 clinical trials

US Patents for MEDI4736

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEDI4736   Start Trial Synergistic combination of immunologic inhibitors for the treatment of cancer The University of Chicago (Chicago, IL)   Start Trial
MEDI4736   Start Trial Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy MedImmune Limited (Cambridge, GB)   Start Trial
MEDI4736   Start Trial Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. (Menlo Park, CA)   Start Trial
MEDI4736   Start Trial Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer AstraZeneca AB (Sodertalje, SE)   Start Trial
MEDI4736   Start Trial Apilimod for use in the treatment of renal cancer LAM Therapeutics, Inc. (Guilford, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEDI4736

Drugname Country Document Number Estimated Expiration Related US Patent
MEDI4736 Canada 2889182 2032-10-26   Start Trial
MEDI4736 European Patent Office 2911669 2032-10-26   Start Trial
MEDI4736 World Intellectual Property Organization (WIPO) 2014066834 2032-10-26   Start Trial
MEDI4736 Australia 2015276173 2034-06-17   Start Trial
MEDI4736 Brazil 112016028964 2034-06-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.